Erratum: Genetic modification of the heart transgenic modification of cardiac lipid and carbohydrate utilization (Journal of Molecular and Cellular Cardiology (2005) 39 (581-593) DOI: 10.1016/j.yjmcc.2005.07.005);Genetic modification of the heart: Transgenic modification of cardiac lipid and carbohydrate utilization

Journal of Molecular and Cellular Cardiology

Volumn 39, Issue 4, 2005, Pages 581-593

  Hartil, K ^a   Charron, M J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes; Disease; Failure; Fatty acids; Function; Glucose; Hypertrophy; Metabolism; Transgenic

Indexed keywords

CARBOHYDRATE; FATTY ACID; GLUCOSE; LACTIC ACID; LIPID;

AEROBIC METABOLISM; CARBOHYDRATE METABOLISM; CARBOHYDRATE TRANSPORT; CYTOSOL; DIABETES MELLITUS; DNA MODIFICATION; ENERGY; GENE EXPRESSION; HEART; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HIGH ENERGY PHOSPHATE; LIPID METABOLISM; LIPID TRANSPORT; MEDICAL RESEARCH; MITOCHONDRION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; TRANSGENIC MOUSE; TRANSGENICS;

ANIMALIA; MUS MUSCULUS;

EID: 24944564702     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2005.11.001     Document Type: Erratum

References (143)

1. K. Carvajal, and R. Moreno-Sanchez Heart metabolic disturbances in cardiovascular diseases Arch. Med. Res. 34 2 2003 89 99
2. A. Avogaro, S. Vigili de Kreutzenberg, C. Negut, A. Tiengo, and R. Scognamiglio Diabetic cardiomyopathy: a metabolic perspective Am. J. Cardiol. 93 8A 2004 13A 16A
3. R. Scognamiglio, A. Avogaro, C. Negut, R. Piccolotto, S. Vigili de Kreutzenberg, and A. Tiengo Early myocardial dysfunction in the diabetic heart: current research and clinical applications Am. J. Cardiol. 93 8A 2004 17A 20A
4. N. Sambandam, G.D. Lopaschuk, R.W. Brownsey, and M.F. Allard Energy metabolism in the hypertrophied heart Heart Fail. Rev. 7 2 2002 161 173
5. W.C. Stanley, G.D. Lopaschuk, and J.G. McCormack Regulation of energy substrate metabolism in the diabetic heart Cardiovasc. Res. 34 1 1997 25 33
6. L.K. Russell, B.N. Finck, and D.P. Kelly Mouse models of mitochondrial dysfunction and heart failure J. Mol. Cell. Cardiol. 38 1 2005 81 91
7. M. Lewandoski Conditional control of gene expression in the mouse Nat. Rev. Genet. 2 10 2001 743 755
8. A.D. Ryding, M.G. Sharp, and J.J. Mullins Conditional transgenic technologies J. Endocrinol. 171 1 2001 1 14
9. J. Robbins Genetic modification of the heart: exploring necessity and sufficiency in the past 10:years J. Mol. Cell. Cardiol. 36 5 2004 643 652
10. A.O. Makinde, J. Gamble, and G.D. Lopaschuk Upregulation of 5′-AMP-activated protein kinase is responsible for the increase in myocardial fatty acid oxidation rates following birth in the newborn rabbit Circ. Res. 80 4 1997 482 489
11. P.J. Randle Fuel selection in animals Biochem. Soc. Trans. 14 5 1986 799 806
12. P.J. Randle, P.B. Garland, C.N. Hales, and E.A. Newsholme The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet 1 1963 785 789
13. P.J. Randle, P.B. Garland, C.N. Hales, E.A. Newsholme, R.M. Denton, and C.I. Pogson Interactions of metabolism and the physiological role of insulin Recent Prog. Horm. Res. 22 1966 1 48
14. P.J. Randle, D.A. Priestman, S.C. Mistry, and A. Halsall Glucose fatty acid interactions and the regulation of glucose disposal J. Cell. Biochem. 55 Suppl 1994 1 11
15. P. Wu, J. Sato, Y. Zhao, J. Jaskiewicz, K.M. Popov, and R.A. Harris Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart Biochem. J. 329 Pt 1 1998 197 201
16. G.J. van der Vusse, J.F. Glatz, H.C. Stam, and R.S. Reneman Fatty acid homeostasis in the normoxic and ischemic heart Physiol. Rev. 72 4 1992 881 940
17. A. Bonen, J.J. Luiken, and J.F. Glatz Regulation of fatty acid transport and membrane transporters in health and disease Mol. Cell. Biochem. 239 1-2 2002 181 192
18. J.F. Brinkmann, N.A. Abumrad, A. Ibrahimi, G.J. van der Vusse, and J.F. Glatz New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36 Biochem. J. 367 Pt 3 2002 561 570
19. J.R. Dyck, and G.D. Lopaschuk Malonyl CoA control of fatty acid oxidation in the ischemic heart J. Mol. Cell. Cardiol. 34 9 2002 1099 1109
20. D.G. Hardie Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase Biochim. Biophys. Acta 1123 3 1992 231 238
21. H.G. Joost, G.I. Bell, J.D. Best, M.J. Birnbaum, M.J. Charron, and Y.T. Chen Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators Am. J. Physiol. Endocrinol. Metab. 282 4 2002 E974 E976
22. E.D. Abel Glucose transport in the heart Front. Biosci. 9 2004 201 215
23. Y. Kashiwaya, K. Sato, N. Tsuchiya, S. Thomas, D.A. Fell, and R.L. Veech Control of glucose utilization in working perfused rat heart J. Biol. Chem. 269 41 1994 25502 25514
24. L. Hue, C. Beauloye, A.S. Marsin, L. Bertrand, S. Horman, and M.H. Rider Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways J. Mol. Cell. Cardiol. 34 9 2002 1091 1097
25. D.A. Okar, A. Manzano, A. Navarro-Sabate, L. Riera, R. Bartrons, and A.J. Lange PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate Trends Biochem. Sci. 26 1 2001 30 35
26. H.S. Leong, M. Grist, H. Parsons, R.B. Wambolt, G.D. Lopaschuk, and R. Brownsey Accelerated rates of glycolysis in the hypertrophied heart: are they a methodological artifact? Am. J. Physiol. Endocrinol. Metab. 282 5 2002 E1039 E1045
27. M. Jain, L. Cui, D.A. Brenner, B. Wang, D.E. Handy, and J.A. Leopold Increased myocardial dysfunction after ischemia-reperfusion in mice lacking glucose-6-phosphate dehydrogenase Circulation 109 7 2004 898 903
28. T. Kempf, and K.C. Wollert Nitric oxide and the enigma of cardiac hypertrophy Bioessays 26 6 2004 608 615
29. B. Nadal-Ginard, J. Kajstura, A. Leri, and P. Anversa Myocyte death, growth, and regeneration in cardiac hypertrophy and failure Circ. Res. 92 2 2003 139 150
30. J.D. Molkentin, and I.G. Dorn 2nd Cytoplasmic signaling pathways that regulate cardiac hypertrophy Annu. Rev. Physiol. 63 2001 391 426
31. H.S. Leong, R.W. Brownsey, J.E. Kulpa, and M.F. Allard Glycolysis and pyruvate oxidation in cardiac hypertrophy - why so unbalanced? Comp. Biochem. Physiol. A Mol. Integr. Physiol. 135 4 2003 499 513
32. M. van Bilsen Energenetics" of heart failure Ann. N. Y. Acad. Sci. 1015 2004 238 249
33. M. van Bilsen, P.J. Smeets, A.J. Gilde, and G.J. van der Vusse Metabolic remodelling of the failing heart: the cardiac burnout syndrome? Cardiovasc. Res. 61 2 2004 218 226
34. G. Stoupakis, and M. Klapholz Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure Heart Dis. 5 3 2003 215 223
35. G. Vescovo, G.B. Ambrosio, and L. Dalla Libera Apoptosis and changes in contractile protein pattern in the skeletal muscle in heart failure Acta Physiol. Scand. 171 3 2001 305 310
36. S. Neubauer, M. Horn, M. Cramer, K. Harre, J.B. Newell, and W. Peters Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy Circulation 96 7 1997 2190 2196
37. K.K. Kalsi, R.T. Smolenski, R.D. Pritchard, A. Khaghani, A.M. Seymour, and M.H. Yacoub Energetics and function of the failing human heart with dilated or hypertrophic cardiomyopathy Eur. J. Clin. Invest. 29 6 1999 469 477
38. S. Rubler, J. Dlugash, Y.Z. Yuceoglu, T. Kumral, A.W. Branwood, and A. Grishman New type of cardiomyopathy associated with diabetic glomerulosclerosis Am. J. Cardiol. 30 6 1972 595 602
39. M.F. Oliver, and L.H. Opie Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias Lancet 343 8890 1994 155 158
40. J. Gamble, and G.D. Lopaschuk Glycolysis and glucose oxidation during reperfusion of ischemic hearts from diabetic rats Biochim. Biophys. Acta 1225 2 1994 191 199
41. F. Okamoto, T. Tanaka, K. Sohmiya, and K. Kawamura CD36 abnormality and impaired myocardial long-chain fatty acid uptake in patients with hypertrophic cardiomyopathy Jpn. Circ. J. 62 7 1998 499 504
42. T. Tanaka, T. Nakata, T. Oka, T. Ogawa, F. Okamoto, and Y. Kusaka Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations J. Lipid Res. 42 5 2001 751 759
43. T.J. Aitman, A.M. Glazier, C.A. Wallace, L.D. Cooper, P.J. Norsworthy, and F.N. Wahid Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats Nat. Genet. 21 1 1999 76 83
44. N. Abumrad, C. Harmon, and A. Ibrahimi Membrane transport of long-chain fatty acids: evidence for a facilitated process J. Lipid Res. 39 12 1998 2309 2318
45. S.E. Campbell, N.N. Tandon, G. Woldegiorgis, J.J. Luiken, J.F. Glatz, and A. Bonen A novel function for FAT/CD36: Involvement in long chain fatty acid transfer into the mitochondria J. Biol. Chem. 2004
46. J.J. Luiken, L.P. Turcotte, and A. Bonen Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles J. Lipid Res. 40 6 1999 1007 1016
47. A. Bonen, D.J. Dyck, A. Ibrahimi, and N.A. Abumrad Muscle contractile activity increases fatty acid metabolism and transport and FAT/CD36 Am. J. Physiol. 276 4 Pt 1 1999 E642 E649
48. J.J. Luiken, S.L. Coort, D.P. Koonen, D.J. van der Horst, A. Bonen, and A. Zorzano Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters Pflugers Arch. 448 1 2004 1 15
49. A. Ibrahimi, A. Bonen, W.D. Blinn, T. Hajri, X. Li, and K. Zhong Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin J. Biol. Chem. 274 38 1999 26761 26766
50. M. Febbraio, N.A. Abumrad, D.P. Hajjar, K. Sharma, W. Cheng, and S.F. Pearce A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism J. Biol. Chem. 274 27 1999 19055 19062
51. H. Irie, I.B. Krukenkamp, J.F. Brinkmann, G.R. Gaudette, A.E. Saltman, and W. Jou Myocardial recovery from ischemia is impaired in CD36-null mice and restored by myocyte CD36 expression or medium-chain fatty acids Proc. Natl. Acad. Sci. USA 100 11 2003 6819 6824
52. C.T. Coburn, F.F. Knapp Jr., M. Febbraio, A.L. Beets, R.L. Silverstein, and N.A. Abumrad Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice J. Biol. Chem. 275 42 2000 32523 32529
53. T. Hajri, X.X. Han, A. Bonen, and N.A. Abumrad Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice J. Clin. Invest. 109 10 2002 1381 1389
54. M. Kuang, M. Febbraio, C. Wagg, G.D. Lopaschuk, and J.R. Dyck Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia Circulation 109 12 2004 1550 1557
55. S.G. Lloyd, P. Wang, H. Zeng, and J.C. Chatham Impact of low-flow ischemia on substrate oxidation and glycolysis in the isolated perfused rat heart Am. J. Physiol. Heart Circ. Physiol. 287 1 2004 H351 H362
56. W. Stremmel, G. Strohmeyer, F. Borchard, S. Kochwa, and P.D. Berk Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes Proc. Natl. Acad. Sci. USA 82 1 1985 4 8
57. F. Schroeder, C.A. Jolly, T.H. Cho, and A. Frolov Fatty acid binding protein isoforms: structure and function Chem. Phys. Lipids 92 1 1998 1 25
58. N.H. Haunerland, and F. Spener Fatty acid-binding proteins - insights from genetic manipulations Prog. Lipid Res. 43 4 2004 328 349
59. J.O. Carey, P.D. Neufer, R.P. Farrar, J.H. Veerkamp, and G.L. Dohm Transcriptional regulation of muscle fatty acid-binding protein Biochem. J. 298 Pt 3 1994 613 617
60. E.J. Murphy, G. Barcelo-Coblijn, B. Binas, and J.F. Glatz Heart fatty acid uptake is decreased in heart-fatty acid binding protein gene-ablated mice J Biol Chem 2004
61. B. Binas, H. Danneberg, J. McWhir, L. Mullins, and A.J. Clark Requirement for the heart-type fatty acid binding protein in cardiac fatty acid utilization FASEB J. 13 8 1999 805 812
62. F.G. Schaap, B. Binas, H. Danneberg, G.J. van der Vusse, and J.F. Glatz Impaired long-chain fatty acid utilization by cardiac myocytes isolated from mice lacking the heart-type fatty acid binding protein gene Circ. Res. 85 4 1999 329 337
63. S. Enerback, and J.M. Gimble Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level Biochim. Biophys. Acta 1169 2 1993 107 125
64. P.H. Weinstock, C.L. Bisgaier, K. Aalto-Setala, H. Radner, R. Ramakrishnan, and S. Levak-Frank Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes J. Clin. Invest. 96 6 1995 2555 2568
65. H. Yagyu, G. Chen, M. Yokoyama, K. Hirata, A. Augustus, and Y. Kako Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy J. Clin. Invest. 111 3 2003 419 426
66. M. Yokoyama, H. Yagyu, Y. Hu, T. Seo, K. Hirata, and S. Homma Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse J. Biol. Chem. 279 6 2004 4204 4211
67. A. Augustus, H. Yagyu, G. Haemmerle, A. Bensadoun, R.K. Vikramadithyan, and S.Y. Park Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression J. Biol. Chem. 279 24 2004 25050 25057
68. E.B. Katz, A.E. Stenbit, K. Hatton, R. DePinho, and M.J. Charron Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4 Nature 377 6545 1995 151 155
69. E.D. Abel, H.C. Kaulbach, R. Tian, J.C. Hopkins, J. Duffy, and T. Doetschman Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart J. Clin. Invest. 104 12 1999 1703 1714
70. S.J. Kaczmarczyk, S. Andrikopoulos, J. Favaloro, A.A. Domenighetti, A. Dunn, and M. Ernst Threshold effects of glucose transporter-4 (GLUT4) deficiency on cardiac glucose uptake and development of hypertrophy J. Mol. Endocrinol. 31 3 2003 449 459
71. A.E. Stenbit, E.B. Katz, J.C. Chatham, D.L. Geenen, S.M. Factor, and R.G. Weiss Preservation of glucose metabolism in hypertrophic GLUT4-null hearts Am. J. Physiol. Heart Circ. Physiol. 279 1 2000 H313 H318
72. M.J. Charron, and E.B. Katz Metabolic and therapeutic lessons from genetic manipulation of GLUT4 Mol. Cell. Biochem. 182 1-2 1998 143 152
73. M.J. Charron, E.B. Katz, and A.L. Olson GLUT4 gene regulation and manipulation J. Biol. Chem. 274 6 1999 3253 3256
74. R.G. Weiss, J.C. Chatham, D. Georgakopolous, M.J. Charron, T. Wallimann, and L. Kay An increase in the myocardial PCr/ATP ratio in GLUT4 null mice FASEB J. 16 6 2002 613 615
75. T.S. Tsao, A.E. Stenbit, J. Li, K.L. Houseknecht, J.R. Zierath, and E.B. Katz Muscle-specific transgenic complementation of GLUT4-deficient mice. Effects on glucose but not lipid metabolism J. Clin. Invest. 100 3 1997 671 677
76. A.E. Stenbit, T.S. Tsao, J. Li, R. Burcelin, D.L. Geenen, and S.M. Factor GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes Nat. Med. 3 10 1997 1096 1101
77. R. Tian, and E.D. Abel Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis Circulation 103 24 2001 2961 2966
78. R. Liao, M. Jain, L. Cui, J. D'Agostino, F. Aiello, and I. Luptak Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice Circulation 106 16 2002 2125 2131
79. Y.J. Suzuki Growth factor signaling for cardioprotection against oxidative stress-induced apoptosis Antioxid. Redox Signal. 5 6 2003 741 749
80. D.D. Belke, S. Betuing, M.J. Tuttle, C. Graveleau, M.E. Young, and M. Pham Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression J. Clin. Invest. 109 5 2002 629 639
81. J. Ren, W.K. Samson, and J.R. Sowers Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease J. Mol. Cell. Cardiol. 31 11 1999 2049 2061
82. P.J. Coffer, J. Jin, and J.R. Woodgett Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation Biochem. J. 335 Pt 1 1998 1 13
83. J. Ren, J. Duan, K.K. Hintz, and B.H. Ren High glucose induces cardiac insulin-like growth factor I resistance in ventricular myocytes: role of Akt and ERK activation Cardiovasc. Res. 57 3 2003 738 748
84. J. Ren Attenuated cardiac contractile responsiveness to insulin-like growth factor I in ventricular myocytes from biobreeding spontaneous diabetic rats Cardiovasc. Res. 46 1 2000 162 171
85. K.E. Bornfeldt, A. Skottner, and H.J. Arnqvist In-vivo regulation of messenger RNA encoding insulin-like growth factor-I (IGF-I) and its receptor by diabetes, insulin and IGF-I in rat muscle J. Endocrinol. 135 2 1992 203 211
86. A. Bereket, C.H. Lang, and T.A. Wilson Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus Horm. Metab. Res. 31 2-3 1999 172 181
87. J. Duan, H.Y. Zhang, S.D. Adkins, B.H. Ren, F.L. Norby, and X. Zhang Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: role of Akt and RhoA Am. J. Physiol. Endocrinol. Metab. 284 2 2003 E366 E376
88. K. Reiss, W. Cheng, A. Ferber, J. Kajstura, P. Li, and B. Li Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice Proc. Natl. Acad. Sci. USA 93 16 1996 8630 8635
89. M.C. Delaughter, G.E. Taffet, M.L. Fiorotto, M.L. Entman, and R.J. Schwartz Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice FASEB J. 13 14 1999 1923 1929
90. J.R. McMullen, T. Shioi, W.Y. Huang, L. Zhang, O. Tarnavski, and E. Bisping The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway J. Biol. Chem. 279 6 2004 4782 4793
91. Q. Li, B. Li, X. Wang, A. Leri, K.P. Jana, and Y. Liu Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy J. Clin. Invest. 100 8 1997 1991 1999
92. F.L. Norby, N.S. Aberle 2nd, J. Kajstura, P. Anversa, and J. Ren Transgenic overexpression of insulin-like growth factor I prevents streptozotocin-induced cardiac contractile dysfunction and beta-adrenergic response in ventricular myocytes J. Endocrinol. 180 1 2004 175 182
93. B. Vanhaesebroeck, S.J. Leevers, K. Ahmadi, J. Timms, R. Katso, and P.C. Driscoll Synthesis and function of 3-phosphorylated inositol lipids Annu. Rev. Biochem. 70 2001 535 602
94. G.Y. Oudit, H. Sun, B.G. Kerfant, M.A. Crackower, J.M. Penninger, and P.H. Backx The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease J. Mol. Cell. Cardiol. 37 2 2004 449 471
95. S.V. Prasad, C. Perrino, and H.A. Rockman Role of phosphoinositide 3-kinase in cardiac function and heart failure Trends Cardiovasc. Med. 13 5 2003 206 212
96. M.A. Crackower, G.Y. Oudit, I. Kozieradzki, R. Sarao, H. Sun, and T. Sasaki Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways Cell 110 6 2002 737 749
97. S.H. Jo, V. Leblais, P.H. Wang, M.T. Crow, and R.P. Xiao Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation Circ. Res. 91 1 2002 46 53
98. L. Barki-Harrington, C. Perrino, and H.A. Rockman Network integration of the adrenergic system in cardiac hypertrophy Cardiovasc. Res. 63 3 2004 391 402
99. T. Shioi, P.M. Kang, P.S. Douglas, J. Hampe, C.M. Yballe, and J. Lawitts The conserved phosphoinositide 3-kinase pathway determines heart size in mice EMBO J. 19 11 2000 2537 2548
100. G.Y. Oudit, M.A. Crackower, U. Eriksson, R. Sarao, I. Kozieradzki, and T. Sasaki Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure Circulation 108 17 2003 2147 2152
101. M.V. Latronico, S. Costinean, M.L. Lavitrano, C. Peschle, and G. Condorelli Regulation of cell size and contractile function by AKT in cardiomyocytes Ann. N. Y. Acad. Sci. 1015 2004 250 260
102. Z.Z. Yang, O. Tschopp, A. Baudry, B. Dummler, D. Hynx, and B.A. Hemmings Physiological functions of protein kinase B/Akt Biochem. Soc. Trans. 32 Pt 2 2004 350 354
103. W.S. Chen, P.Z. Xu, K. Gottlob, M.L. Chen, K. Sokol, and T. Shiyanova Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene Genes Dev. 15 17 2001 2203 2208
104. H. Cho, G.B. Nam, S.H. Lee, Y.E. Earm, and W.K. Ho Phosphatidylinositol 4,5-bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of acetylcholine-activated K(+) channels in mouse atrial myocytes J. Biol. Chem. 276 1 2001 159 164
105. H. Cho, J. Mu, J.K. Kim, J.L. Thorvaldsen, Q. Chu, and E.B. Crenshaw 3rd Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta) Science 292 5522 2001 1728 1731
106. R.S. Garofalo, S.J. Orena, K. Rafidi, A.J. Torchia, J.L. Stock, and A.L. Hildebrandt Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta J. Clin. Invest. 112 2 2003 197 208
107. Y. Fujio, T. Nguyen, D. Wencker, R.N. Kitsis, and K. Walsh Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart Circulation 101 6 2000 660 667
108. I. Shiraishi, J. Melendez, Y. Ahn, M. Skavdahl, E. Murphy, and S. Welch Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes Circ. Res. 94 7 2004 884 891
109. S.A. Cook, T. Matsui, L. Li, and A. Rosenzweig Transcriptional effects of chronic Akt activation in the heart J. Biol. Chem. 277 25 2002 22528 22533
110. T. Matsui, L. Li, J.C. Wu, S.A. Cook, T. Nagoshi, and M.H. Picard Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart J. Biol. Chem. 277 25 2002 22896 22901
111. G. Condorelli, A. Drusco, G. Stassi, A. Bellacosa, R. Roncarati, and G. Iaccarino Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice Proc. Natl. Acad. Sci. USA 99 19 2002 12333 12338
112. T. Shioi, J.R. McMullen, P.M. Kang, P.S. Douglas, T. Obata, and T.F. Franke Akt/protein kinase B promotes organ growth in transgenic mice Mol. Cell. Biol. 22 8 2002 2799 2809
113. S. Kovacic, C.L. Soltys, A.J. Barr, I. Shiojima, K. Walsh, and J.R. Dyck Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart J. Biol. Chem. 278 41 2003 39422 39427
114. W.W. Winder Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle J. Appl. Physiol. 91 3 2001 1017 1028
115. D.G. Hardie AMP-activated protein kinase: the guardian of cardiac energy status J. Clin. Invest. 114 4 2004 465 468
116. D.G. Hardie, J.W. Scott, D.A. Pan, and E.R. Hudson Management of cellular energy by the AMP-activated protein kinase system FEBS Lett. 546 1 2003 113 120
117. N. Sambandam, and G.D. Lopaschuk AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart Prog. Lipid Res. 42 3 2003 238 256
118. T.A. Hopkins, J.R. Dyck, and G.D. Lopaschuk AMP-activated protein kinase regulation of fatty acid oxidation in the ischaemic heart Biochem. Soc. Trans. 31 Pt 1 2003 207 212
119. M. Arad, D.W. Benson, A.R. Perez-Atayde, W.J. McKenna, E.A. Sparks, and R.J. Kanter Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy J. Clin. Invest. 109 3 2002 357 362
120. E. Blair, C. Redwood, H. Ashrafian, M. Oliveira, J. Broxholme, and B. Kerr Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis Hum. Mol. Genet. 10 11 2001 1215 1220
121. M. Arad, I.P. Moskowitz, V.V. Patel, F. Ahmad, A.R. Perez-Atayde, and D.B. Sawyer Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy Circulation 107 22 2003 2850 2856
122. D. Carling The AMP-activated protein kinase cascade-a unifying system for energy control Trends Biochem. Sci. 29 1 2004 18 24
123. N. Henin, M.F. Vincent, and G. Van den Berghe Stimulation of rat liver AMP-activated protein kinase by AMP analogues Biochim. Biophys. Acta 1290 2 1996 197 203
124. R. Tian, N. Musi, J. D'Agostino, M.F. Hirshman, and L.J. Goodyear Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy Circulation 104 14 2001 1664 1669
125. R.R. Russell 3rd, R. Bergeron, G.I. Shulman, and L.H. Young Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR Am. J. Physiol. 277 2 Pt 2 1999 H643 H649
126. A.S. Marsin, L. Bertrand, M.H. Rider, J. Deprez, C. Beauloye, and M.F. Vincent Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia Curr. Biol. 10 20 2000 1247 1255
127. R.R. Russell 3rd, J. Li, D.L. Coven, M. Pypaert, C. Zechner, and M. Palmeri AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury J. Clin. Invest. 114 4 2004 495 503
128. R.F. Kletzien, P.K. Harris, and L.A. Foellmi Glucose-6-phosphate dehydrogenase: a "housekeeping" enzyme subject to tissue-specific regulation by hormones, nutrients, and oxidant stress FASEB J. 8 2 1994 174 181
129. J.P. Kehrer, and L.G. Lund Cellular reducing equivalents and oxidative stress Free Radic. Biol. Med. 17 1 1994 65 75
130. A. Singh, K.J. Lee, C.Y. Lee, R.D. Goldfarb, and M.F. Tsan Relation between myocardial glutathione content and extent of ischemia-reperfusion injury Circulation 80 6 1989 1795 1804
131. F. Gao, C.L. Yao, E. Gao, Q.Z. Mo, W.L. Yan, and R. McLaughlin Enhancement of glutathione cardioprotection by ascorbic acid in myocardial reperfusion injury J. Pharmacol. Exp. Ther. 301 2 2002 543 550
132. R. Ferrari, C. Ceconi, S. Curello, A. Cargnoni, O. Alfieri, and A. Pardini Oxygen free radicals and myocardial damage: protective role of thiol-containing agents Am. J. Med. 91 3C 1991 95S 105S
133. R. Bolli, M.O. Jeroudi, B.S. Patel, C.M. DuBose, E.K. Lai, and R. Roberts Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog Proc. Natl. Acad. Sci. USA 86 12 1989 4695 4699
134. J.L. Zweier, J.T. Flaherty, and M.L. Weisfeldt Direct measurement of free radical generation following reperfusion of ischemic myocardium Proc. Natl. Acad. Sci. USA 84 5 1987 1404 1407
135. J.M. Downey Free radicals and their involvement during long-term myocardial ischemia and reperfusion Annu. Rev. Physiol. 52 1990 487 504
136. W.N. Tian, L.D. Braunstein, K. Apse, J. Pang, M. Rose, and X. Tian Importance of glucose-6-phosphate dehydrogenase activity in cell death Am. J. Physiol. 276 5 Pt 1 1999 C1121 C1131
137. S. Sanders, D.P. Smith, G.A. Thomas, and E.D. Williams A glucose-6-phosphate dehydrogenase (G6PD) splice site consensus sequence mutation associated with G6PD enzyme deficiency Mutat. Res. 374 1 1997 79 87
138. W. Cheng, Y.X. Fu, J.M. Porres, D.A. Ross, and X.G. Lei Selenium-dependent cellular glutathione peroxidase protects mice against a pro-oxidant-induced oxidation of NADPH, NADH, lipids, and protein FASEB J. 13 11 1999 1467 1475
139. W.H. Cheng, Y.S. Ho, B.A. Valentine, D.A. Ross, G.F. Combs Jr., and X.G. Lei Cellular glutathione peroxidase is the mediator of body selenium to protect against paraquet lethality in transgenic mice J. Nutr. 128 7 1998 1070 1076
140. T. Yoshida, M. Watanabe, D.T. Engelman, R.M. Engelman, J.A. Schley, and N. Maulik Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia reperfusion injury J. Mol. Cell. Cardiol. 28 8 1996 1759 1767
141. J.P. McClung, C.A. Roneker, W. Mu, D.J. Lisk, P. Langlais, and F. Liu Development of insulin resistance and obesity in mice overexpressing cellular glutathione peroxidase Proc. Natl. Acad. Sci. USA 101 24 2004 8852 8857
142. B.N. Finck, J.J. Lehman, T.C. Leone, M.J. Welch, M.J. Bennett, and A. Kovacs The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus J. Clin. Invest. 109 1 2002 121 130
143. H.C. Chiu, A. Kovacs, D.A. Ford, F.F. Hsu, R. Garcia, and P. Herrero A novel mouse model of lipotoxic cardiomyopathy J. Clin. Invest. 107 7 2001 813 822